Pimavanserin

ApprovedWithdrawn

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Insomnia Chronic

Conditions

Insomnia Chronic, Posttraumatic Stress Disorder

Trial Timeline

Dec 15, 2022 → Dec 15, 2023

NCT ID

NCT04809116

About Pimavanserin

Pimavanserin is a approved stage product being developed by Acadia Pharmaceuticals for Insomnia Chronic. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04809116. Target conditions include Insomnia Chronic, Posttraumatic Stress Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05796167	Phase 1	Withdrawn	Jan 27, 2023	Jun 24, 2024	Parkinson Disease
NCT05357612	Approved	Recruiting	Jan 23, 2023	Aug 1, 2026	Neurodegenerative Diseases
NCT04809116	Approved	Withdrawn	Dec 15, 2022	Dec 15, 2023	Insomnia Chronic
NCT05555615	Phase 2/3	Terminated	Nov 2, 2022	Feb 14, 2025	Irritability Associated With Autism Spectrum Disorder
NCT04292223	Approved	Completed	Feb 10, 2020	Apr 26, 2022	Parkinson Disease Psychosis
NCT04000009	Phase 3	Terminated	Jun 6, 2019	Feb 22, 2021	Adjunctive Treatment of Major Depressive Disorder
NCT03623321	Phase 3	Completed	Jul 17, 2018	May 5, 2023	Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03482882	Phase 2	Completed	Mar 9, 2018	Jul 24, 2019	Treatment of Depression in Adults With Parkinson's Disease (PD)
NCT03118947	Phase 2	Completed	Feb 23, 2017	Feb 25, 2019	Agitation and Aggression in Alzheimer's Disease
NCT03121586	Phase 3	Terminated	Jan 1, 2017	May 30, 2024	Schizophrenia
NCT03018340	Phase 2	Completed	Dec 1, 2016	Oct 1, 2018	Adjunctive Treatment of Major Depressive Disorder

Competing Products

20 competing products in Insomnia Chronic

See all competitors

Product	Company	Stage	Hype Score
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2	Idorsia	Phase 2	47
Zolpidem (Myslee®) + placebo	Astellas Pharma	Approved	85
zolpidem	Astellas Pharma	Approved	85
Mirtazapine Tablets	Sun Pharmaceutical	Approved	85
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)	Eisai	Approved	85
E2006 1.0 mg + E2006 2.5 mg + E2006 5.0 mg + E2006 10.0 mg + E2006 25.0 mg + E2006 50.0 mg + E2006 100 mg + E2006 200 mg + Zolpidem 10 mg + E2006 Matched Placebo or Zolpidem Matched Placebo + E2006 Matched Placebo	Eisai	Phase 1	33
Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant-matched placebo. + Flurazepam 30 mg	Eisai	Phase 1	33
E2006	Eisai	Phase 1	33
Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placebo	Eisai	Phase 3	77
LEM 5 mg + LEM 10 mg	Eisai	Phase 3	77
Eszopiclone	Eisai	Pre-clinical	23
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mg	Eisai	Phase 2/3	65
lemborexant + Placebo	Eisai	Phase 3	77
E2006 + Placebo	Eisai	Phase 2	52
Zolpidem tablets + Suvorexant tablets, over-encapsulated + Lemborexant tablets + Placebo lemborexant + Placebo zolpidem + Placebo suvorexant	Eisai	Phase 1	33
Eszopiclone	Eisai	Pre-clinical	23
Eszopiclone 1 mg- Elderly + Eszopiclone 2 mg- Elderly + Eszopiclone 3 mg- Non-elderly + Eszopiclone 2 mg- Non-elderly	Eisai	Phase 3	77
Eszopiclone 3 mg + Eszopiclone 1 mg	Eisai	Phase 1	33
LY2624803	Eli Lilly	Phase 1	33
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets	Eli Lilly	Phase 1	33

Other Products from Acadia Pharmaceuticals

PimavanserinApproved

PimavanserinPhase 3

Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + PlaceboPhase 3

Pimavanserin + PlaceboPhase 3